Prelude TherapeuticsPRLD
Market Cap: 318M
About: Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Employees: 128
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
9% more capital invested
Capital invested by funds: $148M [Q4 2023] → $162M (+$13.9M) [Q1 2024]
4% more funds holding
Funds holding: 56 [Q4 2023] → 58 (+2) [Q1 2024]
1.04% less ownership
Funds ownership: 63.33% [Q4 2023] → 62.29% (-1.04%) [Q1 2024]
27% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 22
Research analyst outlook
2 Wall Street Analysts provided 1 year price forecasts over the past 6 months
2 analyst ratings
JMP Securities Reni Benjamin | 21%upside $7 | Market Outperform Initiated | 13 Mar 2024 |
HC Wainwright & Co. Robert Burns | 14%downside $5 | Neutral Downgraded | 20 Feb 2024 |